Medicines Updates and Statements

09.17.2021

Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content

09.03.2021

The Bristol-Myers Squibb-Pfizer Alliance is pleased with the decision by the U.S. Court of Appeals for the Federal Circuit upholding the Eliquis®Patents

09.01.2021

FDA Issues Drug Safety Communication Related to Current XELJANZ® Label

08.13.2021

Pfizer Expands Voluntary Nationwide Recall to include Four Additional Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content

08.13.2021

Pfizer Expands Voluntary Nationwide Recall to include Four Additional Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content

07.16.2021

Pfizer Issues A Voluntary Nationwide Recall for Twelve Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content

06.11.2021

XELJANZ® Safety Review Recommendation Issued in the European Union

05.04.2021

Hospira Issues A Voluntary Nationwide Recall for One Lot of Sterile Water for Injection, USP, Due to the Potential Presence of Visible Particulate

05.04.2021

Hospira Issues A Voluntary Nationwide Recall for One Lot of 0.5% Bupivacaine Hydrochloride Injection, USP and One Lot of 1% Lidocaine HCl Injection, USP Due to Mislabeling

06.16.2020

Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

05.01.2020

Pfizer Receives Positive CHMP Opinion for DAURISMOTM (glasdegib)for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

01.23.2020

Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts